Checkmate Pharmaceuticals, Inc. ( CMPI) Stock. Should you Buy or Sell? $ 10.50
0.00 (0.00 %)
Checkmate Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | CMPI |
| Price | $10.50 |
| Beta | 0.000 |
| Volume Avg. | $233.02 thousand |
| Market Cap | $227.12 M |
| 52 Week Range | $2.0 - $10.5 |
Checkmate Pharmaceuticals, Inc. opened the day at $10.50 which is 0.00 % on yesterday's close. Checkmate Pharmaceuticals, Inc. has a 52 week high of $10.5 and 52 week low of $2.0, which is a difference of $8.5. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $227.12 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Checkmate Pharmaceuticals, Inc. for $227.12 M, it would take 15 years to get your money back. Checkmate Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Checkmate Pharmaceuticals, Inc. Stock Forecast - Is Checkmate Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -3.597 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing Checkmate Pharmaceuticals, Inc.
| Price Book Value Ratio | 4.129 | Price To Book Ratio | 4.129 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -3.597 |
How liquid is Checkmate Pharmaceuticals, Inc.
| Current Ratio | 5.201 |
| Quick Ratio | 5.027 |
Debt
| Debt Ratio | 0.178 | Debt Equity Ratio | 0.217 |
| Long Term Debt To Capitalization | 0.000 | Total Debt To Capitalization | 0.000 |
Latest news about Checkmate Pharmaceuticals, Inc.
Checkpoint Pharmaceuticals lands a premium-rich buyout offer from biotech heavyweight Regeneron.
Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it. The post Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to acquire the company for $10.50 per share in cash. Checkmate's lead investigational candidate.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) will acquire Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) for $10.50 per share, equivalent to a total equity value of approximately $250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary.
Here's what you need to know about trading penny stocks on April 19th The post Hot Penny Stocks to Buy? 3 to Watch As CMPI Stock Shoots Up 320% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
About Checkmate Pharmaceuticals, Inc.
Description :
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
